This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages without signing in

Non-steroidal anti-inflammatory drugs (NSAIDs) and venous thromboembolism (VTE)

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Non-steroidal anti-inflammatory drugs (NSAIDs) and venous thromboembolism (VTE)

Selective or non-selective NSAIDs two-fold or greater increase the risk of venous thromboembolism (1)

  • NSAIDs increase the risk of not only venous but also arterial thromboembolism (1)
    • PGI2 inhibition, which has an antithrombotic effect with COX-2 inhibition, may increase the thrombosis risk
    • both use of traditional NSAIDs, such as ibuprofen, diclofenac, and naproxen, and use of newer highly selective cyclo-oxygenase-2 inhibitors have been linked to an increased risk of both arterial and venous thromboses (2)
    • thrombosis tendency is higher in COX-2 selective inhibitors
      • via their targeted inhibition of cyclo-oxygenase enzymes, NSAIDs promote platelet aggregation, which contributes to activation of the coagulation system and thereby potentially to the formation of a venous thrombosis (2)
      • COX-2 suppression disrupts thromboxane A2/PGI2 balance in favor of thromboxane A2
      • by suppressing COX-1 over 95%, an antithrombotic effect occurs
  • Meaidi et al undertook a study to assess the influence of concomitant use of hormonal contraception and non-steroidal anti-inflammatory drugs (NSAIDs) on the risk of venous thromboembolism
    • analysis of Danish registry data (2.0 million women followed for 21.0 -million-person years) found NSAID use linked to venous thromboembolism, the risk of which was significantly larger with concomitant use of high/medium risk vs. low/no risk hormonal contraception
    • NSAID use was positively associated with the development of venous thromboembolism in women of reproductive age
      • number of extra venous thromboembolic events with NSAID use compared with non-use was significantly larger with concomitant use of high/medium risk hormonal contraception compared with concomitant use of low/no risk hormonal contraception
      • authors state that "...women needing both hormonal contraception and regular use of NSAIDs should be advised accordingly..."
  • in a study among patients with knee osteoarthritis, the authors found:
    • among NSAIDs, the degree of VTE (venous thromboembolism) risk was dependent on the specific NSAID (3)
      • as compared with the 63% increase in the risk among current diclofenac users and 49% increase in current ibuprofen users, the risk was not increased at all among current naproxen users

VTE risk with concomitant use of hormonal contraception and NSAID

A large Danish cohort study concluded (4):

  • NSAID use was positively associated with the development of venous thromboembolism in women of reproductive age
    • number of extra venous thromboembolic events with NSAID use compared with non-use was significantly larger with concomitant use of high/medium risk hormonal contraception compared with concomitant use of low/no risk hormonal contraception
      • in the study, definitions of the risk of hormonal contraception were:
        • high-risk hormonal contraceptives
          • included combined oestrogen and progestin patch, vaginal ring, and tablets containing 50 µg ethinyl oestradiol, or the progestins desogestrel, gestodene, drospirenone, or the anti-androgen cyproterone
        • medium-risk hormonal contraception included all other combined oral contraceptives as well as the medroxyprogesterone injection.
        • low risk/no-risk hormonal contraceptives were considered as progestin-only tablets, implants, and hormone intrauterine devices
      • numbers of extra venous thromboembolic events per 100,000 women over the first week of NSAID treatment compared with non-use of NSAIDs were:
        • 4 (3 to 5) in women not using hormonal contraception,
        • 23 (19 to 27) in women using high-risk hormonal contraception,
        • 11 (7 to 15) in those using medium-risk hormonal contraception, and
        • 3 (0 to 5) in users of low/no risk hormonal contraception
    • women needing both hormonal contraception and regular use of NSAIDs should be advised accordingly

Reference:

  1. Cumhur Cure M, Kucuk A, Cure E. NSAIDs may increase the risk of thrombosis and acute renal failure in patients with COVID-19 infection. Therapie. 2020 Jul-Aug;75(4):387-388. doi: 10.1016/j.therap.2020.06.012. Epub 2020 Jun 27. PMID: 32636031; PMCID: PMC7320673
  2. Meaidi A, Mascolo A, Sessa M, Toft-Petersen A P, Skals R, Gerds T A et al. Venous thromboembolism with use of hormonal contraception and non-steroidal anti-inflammatory drugs: nationwide cohort study BMJ 2023; 382:e074450 doi:10.1136/bmj-2022-074450
  3. Lee T, Lu N, Felson DT, Choi HK, Dalal DS, Zhang Y, Dubreuil M. Use of non-steroidal anti-inflammatory drugs correlates with the risk of venous thromboembolism in knee osteoarthritis patients: a UK population-based case-control study. Rheumatology (Oxford). 2016 Jun;55(6):1099-105
  4. Meaidi A, Mascolo A, Sessa M, Toft-Petersen A P, Skals R, Gerds T A et al. Venous thromboembolism with use of hormonal contraception and non-steroidal anti-inflammatory drugs: nationwide cohort study. BMJ 2023; 382:e074450

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.